Integrated Actionable Aging Assessment for Cancer Patients Pilot

Summary

Aging is the greatest risk factor for cancer incidence and mortality. Geriatric screening is recommended to help with treatment discussions, inform intensity of treatment, and identify supportive care needs. Despite a strong evidence base, geriatric assessments are not implemented routinely in oncologic clinics. Similarly, important information on social determinants of health, mental health, and health behaviors are inconsistently assessed, and almost never in an integrated fashion. In an effort to support clinicians delivering the recommended goal-concordant care, the investigators will integrate assessment of geriatric issues, health behaviors, mental health, and social determinants of health into an efficient, actionable contextual assessment system for older cancer patients called Integrated Aging Assessment for Action for Cancer Patients (IA3-CP). The investigators will use D\&I strategies including co-creation engagement approaches and form-function methods to develop workflow processes that feasibly integrate the IA3-CP into usual initial assessment with the oncology team. Our objective is to develop and conduct a randomized pilot of the IA3-CP system and hypothesize that our results will show it can be implemented consistently, acted on, improve quality of care, and enhance patient-provider interactions.

Conditions

• Breast Cancer
• Hodgkin Lymphoma
• Kidney Cancer
• Leukemia
• Lymphoid Leukemia
• Multiple Myeloma
• Myeloid Leukemia
• Monocytic Leukemia
• Prostate Cancer
• Bladder Cancer

Interventions

OTHER

Assessment tool IA3-CP with SDoH

Each patient randomly assigned to IA3-CP with SDoH study arm will complete a pre-visit assessment tool including SDoH. Feedback is provided to provider and patient.

OTHER

Assessment tool IA3-CP without SDoH

Each patient randomly assigned to IA3-CP only study arm will complete a pre-visit assessment tool excluding SDoH. Feedback is provided to provider and patient.

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• University of Colorado, Denver

  lead OTHER

Principal Investigators

• Russell E Glasgow · University of Colorado, Denver

Study Design

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

65 Years

Max Age

111 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-03-01

Primary Completion

2024-08-06

Completion

2026-12-31

Countries

• United States

Study Locations